HMRC VAT Notice 1004: Zero-Rating Free Medicines for UK Clinical Trials

• HMRC VAT Notice 1004 introduces VAT zero-rating for certain free medicines in the UK, effective from 23 June 2026.
• This zero-rating applies to medicines supplied free for NHS treatment, clinical trials, and continued post-trial care.
• Investigational and non-investigational medicinal products for MHRA-authorized clinical trials are zero-rated from 28 October 2026, following a transitional period.
• Medicines for continued treatment of the same patient with the same product after a clinical trial can also be zero-rated.
• Businesses can correct VAT accounted for at the standard rate between 23 June 2026 and 27 October 2026 if supplies now qualify for zero-rating.

These significant VAT changes for medicines supplied free of charge in the UK took effect from 23 June 2026.

The UK tax authority, HMRC, has issued updated guidance, VAT Notice 1004, detailing the conditions under which certain medicines supplied free of charge can qualify for VAT zero-rating. These significant VAT changes for medicines supplied free of charge in the UK took effect from 23 June 2026. Prior to this date, any deemed supplies of such medicines were subject to the standard 20% VAT rate.

This new zero-rating provision applies broadly to medicinal products provided without charge for several key purposes. These include medicines used in the context of NHS treatment, those supplied for use in clinical trials, and products designated for continued treatment of patients following the conclusion of a clinical trial. The introduction of this specific zero-rate aims to clarify and standardize the VAT treatment for these essential supplies.

A crucial aspect of the updated guidance concerns medicines utilized in clinical research. Both investigational medicinal products (IMPs) and non-investigational medicinal products are eligible for VAT zero-rating when supplied free of charge for use in a clinical trial that has received authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). This provision is outlined under item 1ZA of the VAT Act 1994.

For clinical trial medicines, a transitional period has been established. While supplies before 23 June 2026 could be treated as samples, effectively resulting in no output tax and full input tax recovery, this approach continued until 27 October 2026. From 28 October 2026 onwards, these supplies are formally treated as zero-rated. Furthermore, the zero-rating extends to continued treatment after a clinical trial has ended. A medicinal product can be zero-rated under item 1ZC(a) if supplied free of charge to the same patient who participated in the trial, provided it is the identical product they received during the study. This applies irrespective of whether there was a prior commitment to supply the medicine post-trial, and covers both IMPs and non-IMPs used during the trial. If the patient's treatment is provided, commissioned, or funded by the NHS, the supply may qualify for zero-rating under item 1ZB or 1ZC(b); otherwise, only item 1ZC(a) applies.

For the purposes of VAT Act 1994 items 1ZB and 1ZC, the definition of a "medicinal product" aligns with that found in Regulation 2(1) of The Human Medicines Regulations 2012. Generally, for a medicinal product to be zero-rated when supplied free of charge, all specified conditions must be met. However, it is important to note that certain products are explicitly excluded from this new zero-rating.

Products already exempt from VAT under Schedule 9, Group 7 of the VAT Act 1994 cannot be zero-rated under these new provisions. An example includes products for therapeutic purposes derived from human blood, which retain their exempt status even if they would otherwise meet the criteria for zero-rating. Supplies of medicines free of charge outside the specific conditions for zero-rating generally remain standard-rated, with a narrow exception for supplies made to an intermediary who then provides the medicine free of charge for a qualifying use.

The introduction of these VAT changes for 23 June 2026 medicines has significant implications for pharmaceutical companies and healthcare providers. The shift from treating clinical trial supplies as "samples" to explicitly zero-rated items from 28 October 2026, following an interim period, necessitates careful accounting adjustments. This ensures that businesses continue to recover all input tax without incurring output tax on these specific free supplies.

Crucially, the guidance also provides an opportunity for retrospective corrections. If VAT was incorrectly accounted for at the standard rate for supplies made between 23 June 2026 and 27 October 2026 that now qualify for zero-rating, businesses are permitted to amend their previously declared VAT. This provision highlights the importance of reviewing past declarations in light of the new rules to ensure compliance and potentially recover overpaid VAT.

Lawyers and compliance officers must advise pharmaceutical clients and healthcare providers on the updated VAT zero-rating rules for medicines supplied free of charge, particularly concerning clinical trials and post-trial treatment, to ensure correct VAT accounting from 23 June 2026 and to identify opportunities for correcting past VAT declarations.

Source: Original reporting via HMRC guidance